文献速递中医内科中药与中成药合理使用

泰淋方联合持续低剂量抗生素治疗复发性尿路感染的多中心随机对照试验

Efficacy and safety of tailin formulation combined with continuous low-dose antibiotic therapy in patients with recurrent urinary tract infection: A multicenter, randomized, controlled clinical trial.
PubMed 文献 · Front Pharmacol · 2022-09-14

本研究为多中心随机对照试验,纳入195例复发性尿路感染患者,比较泰淋方联合持续低剂量抗生素(CLAT)与单用CLAT治疗12周的疗效与安全性;联合组有效率高、复发率低,且肾小管损伤标志物及促纤维化因子下降更显著,中医症状改善更明显,未见明显不良反应。

要点

  • 泰淋方联合CLAT可提高复发性尿路感染治疗有效率并降低复发率
  • 联合治疗可降低尿NAG、β2-MG及MCP-1、TGF-β1水平,提示肾小管保护与抗纤维化潜力
  • 联合治疗改善中医症状,且未观察到明显不良反应

核心结论

  • 泰淋方联合持续低剂量抗生素治疗复发性尿路感染,在降低复发率、减轻非感染相关躯体症状及保护肾小管和抗纤维化方面优于单用抗生素。

研究设计与样本

  • 多中心、随机、对照临床试验,患者按1:1分配接受泰淋方联合CLAT或单用CLAT治疗12周,最终分析195例。

主要发现

  • 联合组有效率和复发率均优于CLAT组(p < 0.01)。
  • 联合组尿NAG和β2-MG较CLAT组显著下降(p < 0.01)。
  • 联合组尿MCP-1和TGF-β1较CLAT组下降(p < 0.05)。
  • rUTI病史月数与尿MCP-1(r = 0.50, p < 0.05)和TGF-β1(r = 0.78, p < 0.01)呈正相关。
  • 中医症状改善组间差异显著(p < 0.01),试验期间未见明显不良反应。

临床怎么用

  • 对于复发性尿路感染患者,可考虑在持续低剂量抗生素治疗基础上联合泰淋方,以降低复发并改善症状。
  • 治疗期间可关注尿NAG、β2-MG及MCP-1、TGF-β1等指标变化,评估肾小管保护与抗纤维化效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Persistent inflammation associated with recurrent urinary tract infection (rUTI) is a crucial inducement of inflammation-driven renal fibrosis (IDRF). Although continuous low-dose antibiotic therapy (CLAT) is the common treatment for rUTI, its clinical efficacy remains unsatisfactory. Tailin formulation (TLF), a Chinese herbal formulation prescribed for treating rUTI, is effective in alleviating symptoms and reducing recurrence. This study was to evaluate the efficacy and safety of TLF combined with CLAT compared with CLAT used alone in patients with rUTI. In this multicenter, randomized, controlled clinical trial, patients were assigned (1:1) to receive either TLF + CLAT or CLAT for 12 weeks. The primary outcome was the effective rate at week 12 of the treatment. The secondary outcomes were the recurrent rate at week 4 and week 12 post treatment; the post-treatment changes in renal tubular injury markers (urinary N-acetyl-β-d-glucosaminidase (NAG) and β2-microglobulin (β2-MG)), profibrotic factors (urinary monocyte chemoattractant protein-1 (MCP-1) and transforming growth factor beta1 (TGF-β1)), and traditional Chinese medicine (TCM) symptoms, and vital signs indicators and serious adverse events (SAEs) were also monitored throughout the trial. A total of 195 patients were included in the final analysis. The TLF + CLAT group had a higher effective rate and a lower recurrence rate than the CLAT group (p < 0.01). Significant decrease of urinary NAG and β2-MG was observed in the TLF + CLAT group vs. CLAT group (p < 0.01), and similar changes were observed in profibrotic factors (urinary MCP-1 and TGF-β1) (p < 0.05), which indicated that TLF might have potential renal tubular protection and anti-fibrosis effects. Additionally, a positive correlation within a certain range was shown in the correlation analysis of medical history (months) of rUTI patients with urinary MCP-1 (r = 0.50, p < 0.05) and TGF-β1 (r = 0.78, p < 0.01). A significant difference was also observed in TCM symptoms (p < 0.01). There were no obvious adverse reactions that occurred during this study. We conclude that TLF combined with CLAT was superior to CLAT used alone in reducing rUTI recurrence, alleviating the non-infection-related physical symptoms and protecting renal tubular and anti-fibrosis, which suggests this novel therapy might be an available treatment with great promise in treating rUTI.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Li T, Xu Y, Yuan G, et al. Efficacy and safety of tailin formulation combined with continuous low-dose antibiotic therapy in patients with recurrent urinary tract infection: A multicenter, randomized, controlled clinical trial. Front Pharmacol. 2022. PMID: 36188617. doi:10.3389/fphar.2022.968980

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。